💊
Piasky
crovalimab
Hemoglobinurie, paroxismale
✅ Geautoriseerd
✅
Geen actieve meldingen
Dit geneesmiddel heeft geen lopende tekorten, veiligheidsbrieven of terugroepacties.
Waarvoor het wordt gebruikt
Piasky as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): In patients with haemolysis with clinical symptom(s) indicative of high disease activity. In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.
⚠️ Patiëntveiligheid
No
Officiële EMA-pagina
https://www.ema.europa.eu/en/medicines/human/EPAR/piasky